1735-P: Participants Achieving HbA1c <8% in Youth Report Greater Treatment Satisfaction with Inhaled Technosphere Insulin vs. Rapid-Acting Analogs

Introduction and Objective: Patient-reported outcomes (PROs) capture dimensions of diabetes care beyond glycemic outcomes, including treatment burden, lifestyle flexibility, perceived hypo/hyperglycemia, and overall treatment satisfaction. Evaluating PROs alongside glycemic targets provides unique insight to patient medication taking and well-being. We assessed whether youth with type 1 or type 2 diabetes who responded well to therapy (HbA1c <8% after 26 weeks) reported greater treatment satisfaction with Inhaled Technosphere Insulin (TI) versus rapid-acting insulin analogs (RAAs) delivered by multiple daily injections (MDI). Methods: INHALE-1 was a randomized pediatric trial (TI vs MDI-based RAA). Post hoc descriptive analyses evaluated change from baseline in Diabetes Treatment Satisfaction Questionnaire status (DTSQs) Teen surveys and Parent surveys (for children <13 years) at Week 26 among participants who achieved HbA1c <8% at Week 26. Between-group comparisons were conducted using a two-tailed t-test. Results: Previously reported primary glycemic outcomes indicated similar HbA1c responses between TI and RAA in the overall cohort. Among participants who met HbA1c<8%, the TI group demonstrated greater improvement in treatment satisfaction from baseline compared to RAA on both Teen (TI n=28, RAA n=26; p=0.02) and Parent (TI n=13, RAA n=23; p=0.01) surveys. Conclusion: In pediatric participants achieving HbA1c <8%, TI produced statistically greater increases in treatment satisfaction in teens and parents of younger participants than RAA, despite similar overall glycemic outcomes. These findings suggest TI may offer quality-of-life benefits beyond glycemic targets compared to RAA, which may be an important factor when discussing insulin options for youth. Disclosure K. Kaiserman: Employee; Current; MannKind Corporation. Stock/Shareholder; Current; MannKind Corporation. J. Sylvan: Employee; Current; MannKind Corporation. L.E. Mycue: Employee; Current; MannKind Corporation. J.K. Rinker: Employee; Current; MannKind Corporation. L. Griparic: Employee; Current; MannKind Corporation. J. Nguyen: Other - Post-Doctoral Fellow (Contractor); Current; MannKind Corporation. J.T. Rittenberry: Employee; Current; MannKind Corporation.